Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Johnson & Johnson (JNJ): Here’s Why It’s Boosting the Dow (.DJI)

Something that sets us Foolish investors apart is that we like to be in control of our own finances. There’s nothing wrong with investing in an index fund, but we like to decide which companies will guide us to a financially healthy retirement.

One very popular stock for many a retirement portfolio –including “The World’s Greatest” — reported this morning, and investors are pleased with what they see. Read below to see why this stock — Johnson & Johnson (NYSE:JNJ) — is up today, and at the end, I’ll offer up access to a special premium report on the company.

Johnson & Johnson (JNJ)

Just the numbers

Actual Vs. Expectations Vs. Q1 2012
Revenue $17.5 billion Beat by $100 million +8.5%
Earnings Per Share $1.44 Beat by $0.04 +5.1%

Sources: E*Trade, SEC filings. These results actually exclude a $600 million, one-time charge for litigation expenses and the company’s acquisition of Synthes.

Because Johnson & Johnson (NYSE:JNJ) is such a massive medical conglomerate, it helps to break down the company into its three segments:

  1. Consumer: Sells over the counter (OTC) medicines and products, accounting for 21% of all sales.
  2. Pharmaceuticals: Develops prescription medications, accounting for 39% of all sales.
  3. Medical devices and diagnostics: Offers larger, more complicated machines to medical establishments, accounting for 40% of all sales.

Source: SEC filings.

Source: SEC filings.

Source: SEC filings.

While it might seem that the slow growth in the consumer sector would be disappointing, it actually was encouraging. The last three years have seen sales of Tylenol and Motrin fall as the company addressed production problems at its Puerto Rico and Pennsylvania plants.

Pharmaceuticals, on the other hand, were both higher than expected and showed tremendous growth. Sales of Invega (a drug for schizophrenia), Stelara (a psoriasis treatment), Simponi (an arthritis medicine), Remicade (an anti-inflammatory), and Prezista (an HIV treatment) all were major contributors to this growth.

And even though sales for medical devices were softer than expected, they still showed solid 10% growth. That was helped primarily by the acquisition of Synthes, as well as sales of electrophysiology and cardiovascular products, and the company’s 1-Day Acuvue disposable contact lenses.

The article Why Johnson & Johnson Stock Is Boosting the Dow originally appeared on Fool.com.

Fool contributor Brian Stoffel owns shares of Johnson & Johnson. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Loading Comments...